兴齐眼药涨2.03%，成交额1.85亿元，主力资金净流入932.08万元

Core Viewpoint - The stock of Xingqi Eye Pharmaceutical has shown a significant increase in price and trading activity, reflecting positive market sentiment and strong financial performance in recent periods [1][2]. Financial Performance - For the first half of 2025, Xingqi Eye Pharmaceutical reported a revenue of 1.163 billion yuan, representing a year-on-year growth of 30.38% [2]. - The net profit attributable to shareholders for the same period was 335 million yuan, marking a substantial increase of 97.75% year-on-year [2]. Stock Performance - As of October 15, the stock price of Xingqi Eye Pharmaceutical was 67.00 yuan per share, with a year-to-date increase of 38.35% [1]. - Over the last five trading days, the stock has risen by 1.93%, while it has decreased by 5.71% over the past 20 days and increased by 25.61% over the last 60 days [1]. Shareholder Information - As of June 30, the number of shareholders for Xingqi Eye Pharmaceutical reached 46,300, an increase of 8.71% from the previous period [2]. - The average number of tradable shares per shareholder increased by 28.79% to 4,066 shares [2]. Dividend Distribution - Since its A-share listing, Xingqi Eye Pharmaceutical has distributed a total of 1.166 billion yuan in dividends, with 985 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest shareholder, holding 3.498 million shares, an increase of 968,000 shares from the previous period [3]. - The Southern CSI 500 ETF ranked as the fourth-largest shareholder with 2.516 million shares, up by 764,100 shares [3].